

# Virginia F Borges

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7735630/publications.pdf>

Version: 2024-02-01

103  
papers

7,058  
citations

57719

44  
h-index

62565

80  
g-index

105  
all docs

105  
docs citations

105  
times ranked

8441  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 48-57.	1.9	6
2	Mammary collagen is under reproductive control with implications for breast cancer. <i>Matrix Biology</i> , 2022, 105, 104-126.	1.5	9
3	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2339-2348.	3.2	20
4	Abstract P1-17-01: Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide. <i>Cancer Research</i> , 2022, 82, P1-17-01-P1-17-01.	0.4	1
5	PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	1.5	17
6	Overall survival is the lowest among young women with postpartum breast cancer. <i>European Journal of Cancer</i> , 2022, 168, 119-127.	1.3	10
7	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. <i>Cancer</i> , 2021, 127, 1021-1028.	2.0	20
8	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 815-821.	1.1	6
9	Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 883-891.	1.1	1
10	Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 640690.	1.3	6
11	Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 412-422.	1.2	14
12	Arm Morbidity After Local Therapy for Young Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6071-6082.	0.7	7
13	Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. <i>Cancer</i> , 2021, 127, 2888-2894.	2.0	23
14	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. <i>Lancet Oncology</i> , The, 2021, 22, 753-754.	5.1	57
15	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. <i>JAMA Oncology</i> , 2021, 7, 845.	3.4	56
16	Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 825-838.	0.7	7
17	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 99.	2.3	11
18	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31

#	ARTICLE	IF	CITATIONS
19	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
20	Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3890-3896.	0.8	0
21	Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. <i>Nature Communications</i> , 2021, 12, 6341.	5.8	19
22	The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	0
23	Chronic pain, health-related quality of life, and employment in working-age cancer survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 179-187.	1.5	28
24	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
25	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 725-733.	0.8	46
26	Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. <i>JAMA Surgery</i> , 2020, 155, 1035.	2.2	62
27	Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. <i>Cancer Medicine</i> , 2020, 9, 8801-8808.	1.3	1
28	Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 56.	2.3	6
29	Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach. <i>Breast Cancer Research</i> , 2020, 22, 128.	2.2	21
30	Characterization of weaning-induced breast involution in women: implications for young women's breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 55.	2.3	24
31	Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 655-663.	1.1	25
32	S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue. <i>Npj Breast Cancer</i> , 2020, 6, 62.	2.3	7
33	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	0.8	331
34	Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival. <i>Oncogene</i> , 2020, 39, 2772-2785.	2.6	23
35	Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?. <i>Cancer Research</i> , 2020, 80, 1790-1798.	0.4	41
36	A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. <i>Molecular Cancer Research</i> , 2019, 17, 131-139.	1.5	92

#	ARTICLE	IF	CITATIONS
37	Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. <i>Breast Journal</i> , 2019, 25, 1104-1110.	0.4	10
38	PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density. <i>Frontiers in Immunology</i> , 2019, 10, 1313.	2.2	15
39	Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 369-382.	1.1	36
40	Employment trends in young women following a breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 207-214.	1.1	22
41	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. <i>Cancer</i> , 2019, 125, 3266-3274.	2.0	37
42	Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. <i>Psycho-Oncology</i> , 2019, 28, 1033-1040.	1.0	15
43	Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. <i>Oncogene</i> , 2019, 38, 4685-4699.	2.6	64
44	IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1223.	1.3	88
45	Association Between Postpartum Breast Cancer Diagnosis and Metastasis and the Clinical Features Underlying Risk. <i>JAMA Network Open</i> , 2019, 2, e186997.	2.8	72
46	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 66-97.	2.3	206
47	Innovations in Personalized and Targeted Therapies for Breast Cancer. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-2.	0.6	1
48	Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 6473-6485.	0.4	50
49	Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. , 2018, 6, 98.		43
50	Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 880-888.	5.1	144
51	Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1214.	3.4	108
52	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-11.	0.6	19
53	Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. <i>International Immunopharmacology</i> , 2018, 63, 282-291.	1.7	145
54	Mucosal Immunity in the Female Murine Mammary Gland. <i>Journal of Immunology</i> , 2018, 201, 734-746.	0.4	58

#	ARTICLE	IF	CITATIONS
55	Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 503-513.	2.0	52
56	Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). <i>Clinical Cancer Research</i> , 2017, 23, 3529-3536.	3.2	112
57	The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 494-503.	2.3	43
58	The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. <i>Cancer Discovery</i> , 2017, 7, 177-187.	7.7	42
59	Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1722-1729.	1.1	23
60	Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. <i>Frontiers in Oncology</i> , 2017, 7, 252.	1.3	31
61	Deciphering Pro-Lymphangiogenic Programs during Mammary Involution and Postpartum Breast Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 227.	1.3	16
62	Quantitative extracellular matrix proteomics to study mammary and liver tissue microenvironments. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 81, 223-232.	1.2	89
63	Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. <i>Practical Radiation Oncology</i> , 2016, 6, e291-e298.	1.1	48
64	Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8272-8277.	3.3	56
65	21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. <i>Journal of Clinical Oncology</i> , 2016, 34, 1995-2002.	0.8	46
66	<i>BRCA1</i> and <i>BRCA2</i> Mutation Testing in Young Women With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 730.	3.4	105
67	Important Role of Menarche in Development of Estrogen Receptorâ€“Negative Breast Cancer in African American Women. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	47
68	Wound healingâ€“like immune program facilitates postpartum mammary gland involution and tumor progression. <i>International Journal of Cancer</i> , 2015, 136, 1803-1813.	2.3	112
69	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
70	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3809-3815.	0.7	81
71	Myoepithelial Cell Differentiation Markers in Ductal Carcinoma in Situ Progression. <i>American Journal of Pathology</i> , 2015, 185, 3076-3089.	1.9	60
72	Parity, Lactation, and Breast Cancer Subtypes in African American Women: Results from the AMBER Consortium. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	162

#	ARTICLE	IF	CITATIONS
73	Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. <i>Cancer</i> , 2014, 120, 2264-2271.	2.0	93
74	Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. <i>Breast Cancer Research</i> , 2014, 16, R31.	2.2	71
75	Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. <i>Neuro-Oncology</i> , 2014, 16, 1006-1009.	0.6	52
76	Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1151-1156.	0.8	313
77	Mammary Gland Involution as an Immunotherapeutic Target for Postpartum Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2014, 19, 213-228.	1.0	40
78	Physiological COX-2 Expression in Breast Epithelium Associates with COX-2 Levels in Ductal Carcinoma in Situ and Invasive Breast Cancer in Young Women. <i>American Journal of Pathology</i> , 2014, 184, 1219-1229.	1.9	33
79	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
80	Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 3901-3912.	3.9	110
81	Genomic Signatures of Pregnancy-Associated Breast Cancer Epithelia and Stroma and their Regulation by Estrogens and Progesterone. <i>Hormones and Cancer</i> , 2013, 4, 140-153.	4.9	46
82	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1711-1722.	2.0	113
83	Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 431-448.	1.1	32
84	Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. <i>Experimental Cell Research</i> , 2013, 319, 1671-1678.	1.2	39
85	Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 549-559.	1.1	175
86	Influence of human immune cells on cancer: studies at the University of Colorado. <i>Immunologic Research</i> , 2013, 55, 22-33.	1.3	13
87	Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. <i>ELife</i> , 2013, 2, e00996.	2.8	42
88	Abstract B099: Postpartum mammary gland involution promotes COX-2 dependent tumor cell invasion of lymphatics. , 2013, , .		0
89	Could NSAIDs become a preventative therapy in pregnancy-associated breast cancer?. <i>Breast Cancer Management</i> , 2012, 1, 39-46.	0.2	3
90	Pregnancy-associated breast cancer. <i>Cancer</i> , 2012, 118, 3226-3228.	2.0	60

#	ARTICLE	IF	CITATIONS
91	Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. <i>Nature Medicine</i> , 2011, 17, 1109-1115.	15.2	318
92	Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 807-816.	0.9	9
93	Alternatively Activated Macrophages and Collagen Remodeling Characterize the Postpartum Involuting Mammary Gland across Species. <i>American Journal of Pathology</i> , 2010, 176, 1241-1255.	1.9	251
94	Pregnancy and Breast Cancer: when They Collide. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2009, 14, 87-98.	1.0	181
95	Hepatic complications of breast cancer. <i>Lancet Oncology</i> , The, 2009, 10, 615-621.	5.1	67
96	Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 475-488.	1.1	49
97	Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 489-501.	1.1	32
98	Microenvironment of the Involuting Mammary Gland Mediates Mammary Cancer Progression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007, 12, 71-82.	1.0	135
99	Spontaneous Fusion with, and Transformation of Mouse Stroma by, Malignant Human Breast Cancer Epithelium. <i>Cancer Research</i> , 2006, 66, 8274-8279.	0.4	80
100	Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. <i>British Journal of Haematology</i> , 2005, 129, 687-700.	1.2	65
101	Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. <i>Clinical Cancer Research</i> , 2004, 10, 4699-4708.	3.2	227
102	Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 46-53.	0.8	278
103	Update on cancer vaccines. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 723-731.	1.0	4